Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Basal-bolus insulin 2:2 vs 2:3 regimens in hospitalized patients with type 2 diabetes mellitus
ChiCTR2100050963Phase 4Recruiting
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of insulin glargine and insulin aspart in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Primary endpoints: fasting blood glucose and 2-hour postprandial blood glucose. Started Dec 2021; status: recruiting.
02
Drugs
insulin glargineinsulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2100050963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050963.